UNVEILING SKELETAL FRAGILITY IN PATIENTS DIAGNOSED WITH MGUS: NO LONGER A CONDITION OF UNDETERMINED SIGNIFICANCE?

J Bone Miner Res. 2014 Dec;29(12):2529-33. doi: 10.1002/jbmr.2387.

Accordingly, this Perspective provides evidence that the «undetermined significance» portion of the MGUS acronym may be best replaced in favor of the term «monoclonal gammopathy of skeletal significance» (MGSS) in order to more accurately reflect the enhanced skeletal risks inherent in this condition.

Autor: Drake MT.
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen